Mallinckrodt is targeting hospitalized patients with Type 1 HRS (meaning the onset of renal and multi-organ failure) with an expected 2 to 4 week median survival. BioVie is targeting ambulatory ascites patients (sometime overlapping with Type 2 HRS) who are severely ill and at risk of progressing to hospitalization with HRS-1. BioVie is trying to prevent them from progressing to Type 1 HRS.
Why agitate a lunatic with a response over a week later? You barely post. Why post then leave others to clear the smoke? If dude starts up again why don't you go at it for a while. Like ur the real passionate one right? Held from 5 to 35 back down? Smh
News 
Market Data 
Discover 
